Sulpiride first appeared in published literature in 1967. Clinical studies show a greater effect on treating the negative symptoms of schizophrenia rather than positive symptoms at low doses, though the effects are more equal at higher doses. Sulpiride is not approved by the FDA, Health Canada, or the EMA; though it is approved in individual European countries.
Sulpiride first appeared in published literature in 1967. Clinical studies show a greater effect on treating the negative symptoms of schizophrenia rather than positive symptoms at low doses, though the effects are more equal at higher doses. Sulpiride is not approved by the FDA, Health Canada, or the EMA; though it is approved in individual European countries.
Sulpiride is indicated for the treatment of acute and chronic schizophrenia.
Stay informed with timely notifications on clinical trials and research advancements.